Effect of Teriparatide on Unstable Pertrochanteric Fractures
Table 3
Outcome measures of patients in the control and teriparatide groups at the last follow-up.
Parameters
Group A
Group B
value
Variables
Age at time of operation (yrs)
81.0 ± 9.3
82.1 ± 7.6
0.254
Body mass index (kg/m2)
21.9 ± 2.5
22.9 ± 3.1
0.117
ASA classification
0.464
ASA I
—
—
—
ASA II
29 (65.9%)
18 (62.1%)
ASA III
15 (34.1%)
11 (37.9%)
Hospital stay (day)
8.6 ± 1.6
7.9 ± 1.6
0.067
BMD of contralateral hip (-score)
−4.0 ± 1.2
−3.9 ± 1.0
0.908
Follow-up (months)
37.3 ± 7.4
36.2 ± 7.1
0.650
Subsequent fracture
Vertebral fracture
7 (15.9%)
3 (10.3%)
0.421
Hip fracture
2 (4.5%)
1 (3.4%)
0.677
Wrist fracture
2 (4.5%)
2 (6.9%)
0.494
Overall subsequent fracture
11 (25%)
5 (17.2%)
0.350
Union time (weeks)
14.3 ± 2.8
11.2 ± 1.6
<0.001*
Tip apex distance (mm)
19.1 ± 2.6
18.8 ± 2.4
0.643
Sliding of lag screw (mm)
9.6 ± 5.3
2.2 ± 1.4
<0.001*
Femoral shortening (mm)
13.2 ± 7.4
4.2 ± 2.6
<0.001*
Varus collapse (degrees)
7.7 ± 4.4
2.6 ± 1.7
<0.001*
Group A: patient without any supplementation of pharmacologic treatment. Group B: patient treated with teriparatide. Values are shown as mean (standard deviation) or as the (%). values for between-group comparison were determined by the chi-squared test and Fisher’s exact test which were used for nominal variables. Student’s -test was used for parametric variables. *Statistically significant ( value < 0.05).
